Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Biotron Limited BITRF OTC

Other OTC • Healthcare • Biotechnology • AU • USD

SharesGrow Score
49/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Biotron Limited (BITRF) is a Biotechnology company in the Healthcare sector, currently trading at $0.03. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Financials: revenue is $2M, +5.7%/yr average growth. Net income is $318,572 (loss), growing at +22.2%/yr. Net profit margin is -17.6% (negative). Gross margin is 100% (+2.9 pp trend).

Balance sheet: total debt is $0 against $551,895 equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 2.23 (strong liquidity). Debt-to-assets is 0%. Total assets: $980,401.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 83/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 50/100 (Partial), Future ?/100 (Fail), Income 10/100 (Fail).

BITRF SharesGrow Score Overview

61/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 83/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BITRF

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✓
GROWTH Pass
83/100
BITRF: +5.7%/yr revenue is, +22.2%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet BITRF: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 2.23 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
BITRF: Gross margin is 100% (+2.9 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
BITRF: Net profit margin is -17.6%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.0011-0.10144
Volume300K
Avg Volume (30D)6.52K
Market Cap$29.15M
Beta (1Y)-0.59
Share Statistics
EPS (TTM)0.00
Shares Outstanding$1B
IPO Date2013-03-22
CEOMichelle Miller GCertAppFin
Financial Highlights & Ratios
Revenue (TTM)$1.81M
Gross Profit$1.81M
EBITDA$-333.81K
Net Income$-318.57K
Operating Income$-338.75K
Total Cash$931.68K
Net Debt$-931.68K
Total Assets$980.4K
Price / Earnings (P/E)-107.2
Price / Sales (P/S)16.07
Analyst Forecast
Company Info
CountryAU
ExchangeOther OTC
CurrencyUSD
ISINAU000000BIT4

Price Chart

Track all markets on TradingView
BITRF
Biotron Limited ↗  ·  Other OTC
Healthcare • Biotechnology
0.00 52WK RANGE 0.10

People Also View

CMVLF
CMVLF
Cellectis S.A.
$3.08
-30.00%
 CVALF
CVALF
Covalon Technologies Ltd.
$1.45
+0.69%
 DMTTF
DMTTF
Small Pharma Inc.
$0.11
-9.69%
 RVXCF
RVXCF
Resverlogix Corp.
$0.08
+4.55%
 CRPOF
CRPOF
Ceapro Inc.
$0.17
-13.04%
 CPMV
CPMV
Mosaic ImmunoEngineering Inc.
$0.70
-6.71%
 CHNXF
CHNXF
ChitogenX Inc.
$0.01
+0.00%
 APTCF
APTCF
Advanced Proteome Therapeutics Corporation
$0.00
+0.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message